- Home
- SNY vs SKYW Comparison
SNY vs SKYW Comparison
Compare SNY & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- SKYW
- Stock Information
- Founded
- SNY 1994
- SKYW 1972
- Country
- SNY France
- SKYW United States
- Employees
- SNY N/A
- SKYW N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- SKYW Air Freight/Delivery Services
- Sector
- SNY Health Care
- SKYW Consumer Discretionary
- Exchange
- SNY Nasdaq
- SKYW Nasdaq
- Market Cap
- SNY 123.6B
- SKYW N/A
- IPO Year
- SNY N/A
- SKYW N/A
- Fundamental
- Price
- SNY $53.63
- SKYW $88.23
- Analyst Decision
- SNY Buy
- SKYW Strong Buy
- Analyst Count
- SNY 2
- SKYW 3
- Target Price
- SNY $62.50
- SKYW $120.67
- AVG Volume (30 Days)
- SNY 3.6M
- SKYW 475.8K
- Earning Date
- SNY 04-24-2025
- SKYW 04-24-2025
- Dividend Yield
- SNY 3.08%
- SKYW N/A
- EPS Growth
- SNY 39.56
- SKYW 219.12
- EPS
- SNY 5.45
- SKYW 8.74
- Revenue
- SNY $48,817,552,946.00
- SKYW $3,672,761,000.00
- Revenue This Year
- SNY $5.35
- SKYW $10.89
- Revenue Next Year
- SNY $6.69
- SKYW $4.14
- P/E Ratio
- SNY $18.87
- SKYW $10.06
- Revenue Growth
- SNY N/A
- SKYW 20.53
- 52 Week Low
- SNY $45.80
- SKYW $64.61
- 52 Week High
- SNY $60.12
- SKYW $135.57
- Technical
- Relative Strength Index (RSI)
- SNY 50.20
- SKYW 50.59
- Support Level
- SNY $50.46
- SKYW $85.17
- Resistance Level
- SNY $51.64
- SKYW $92.84
- Average True Range (ATR)
- SNY 1.60
- SKYW 4.95
- MACD
- SNY 0.15
- SKYW 0.81
- Stochastic Oscillator
- SNY 65.92
- SKYW 73.48
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.